Učitavanje...
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects
BACKGROUND. Individuals treated with the cholesteryl ester transfer protein (CETP) inhibitor anacetrapib exhibit a reduction in both LDL cholesterol and apolipoprotein B (ApoB) in response to monotherapy or combination therapy with a statin. It is not clear how anacetrapib exerts these effects; ther...
Spremljeno u:
| Izdano u: | J Clin Invest |
|---|---|
| Glavni autori: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society for Clinical Investigation
2015
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4497759/ https://ncbi.nlm.nih.gov/pubmed/25961461 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI80025 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|